Tamiflu(oseltamivir)
Tamiflu (oseltamivir) is a small molecule pharmaceutical. Oseltamivir was first approved as Tamiflu on 1999-10-27. It is used to treat human influenza in the USA. It has been approved in Europe to treat human influenza.
Download report
Favorite
COVID-19
Commercial
Trade Name
FDA
EMA
Tamiflu (generic drugs available since 2016-08-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oseltamivir phosphate | ANDA | 2023-06-07 |
| tamiflu | New Drug Application | 2023-02-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| human influenza | EFO_0007328 | D007251 | J11.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
125 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | 12 | 21 | 17 | 26 | 9 | 80 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | — | 3 | 1 | — | 5 |
| Respiratory tract infections | D012141 | J06.9 | — | — | 2 | 1 | — | 3 | |
| Therapeutic equivalency | D013810 | 1 | — | — | 1 | — | 2 | ||
| St elevation myocardial infarction | D000072657 | — | — | — | 1 | — | 1 | ||
| Sars-cov-2 | D000086402 | — | — | — | 1 | — | 1 | ||
| Combination drug therapy | D004359 | — | — | — | 1 | — | 1 | ||
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | 1 | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | 1 | 1 | 2 | — | — | 4 | |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | 1 | — | — | 1 |
| Virus shedding | D017201 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 11 | 1 | — | — | — | 12 | ||
| Virus diseases | D014777 | B34 | 1 | 2 | — | — | — | 3 | |
| Influenza a virus | D009980 | NCBITaxon_11320 | — | 2 | — | — | — | 2 | |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | — | — | — | 1 |
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | — | 1 |
| Influenza in birds | D005585 | J09.X | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | 2 | — | — | — | — | 2 | ||
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | 1 | — | — | — | — | 1 | |
| Pulmonary infarction | D054060 | EFO_1001408 | 1 | — | — | — | — | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 | |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OSELTAMIVIR |
| INN | oseltamivir |
| Description | Oseltamivir is a cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza. It has a role as a prodrug, an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor, an antiviral drug, an environmental contaminant and a xenobiotic. It is a cyclohexenecarboxylate ester, an amino acid ester, a primary amino compound and a member of acetamides. |
| Classification | Small molecule |
| Drug class | antivirals: neuraminidase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |
Identifiers
| PDB | — |
| CAS-ID | 196618-13-0 |
| RxCUI | 260101 |
| ChEMBL ID | CHEMBL1229 |
| ChEBI ID | 7798 |
| PubChem CID | 65028 |
| DrugBank | DB00198 |
| UNII ID | 20O93L6F9H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Tamiflu - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Oseltamivir - Amneal Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,087 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
494 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more